Revelation Biosciences (REVB) Income from Continuing Operations (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Income from Continuing Operations of 2706659.0 for Q4 2025, down 21.23% year-over-year from 3436027.57 in Q4 2024, and down 39.3% quarter-over-quarter from 1943011.0 in Q3 2025.
Revelation Biosciences (REVB) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Income from Continuing Operations for 5 consecutive years, with 2706659.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 21.23% year-over-year to 2706659.0; the TTM figure through Dec 2025 stood at 9205886.0 (down 7.87% YoY), while the FY2025 annual figure was 26670814.0, down 215.48% from the prior year.
- Income from Continuing Operations declined to 2706659.0 in Q4 2025 per REVB's latest filing, from 1943011.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1216656.0 in Q3 2022 and bottomed at 12829814.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 3035886.6 across 5 years, with a median of 2336382.5 in 2021.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 705.75% — and 2024, when it soared 82.6%.
- Revelation Biosciences' Income from Continuing Operations stood at 4214285.0 in 2021, then surged by 62.22% to 1592291.0 in 2022, then sank by 705.75% to 12829814.0 in 2023, then jumped by 82.6% to 2232718.0 in 2024, then retreated by 21.23% to 2706659.0 in 2025.
- Business Quant data shows REVB's Income from Continuing Operations at 2706659.0 in Q4 2025, 1943011.0 in Q3 2025, and 2461229.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | -3.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.66 Mn |
| Dec 31, 2025 | -2.71 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | -2.23 Mn |
| Sep 30, 2024 | -1.81 Mn |
| Jun 30, 2024 | -2.55 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Dec 31, 2023 | -12.83 Mn |
| Sep 30, 2023 | -2.81 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -1.71 Mn |
| Dec 31, 2022 | -1.59 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -1.89 Mn |
| Mar 31, 2022 | -6.64 Mn |
| Dec 31, 2021 | -4.21 Mn |
| Sep 30, 2021 | -3.04 Mn |
| Jun 30, 2021 | -2.44 Mn |